



# *Cent Gardes Conference: HIV Vaccines*

*In memory of Dr. Charles Mérieux*

*Organized by Fondation Mérieux*

*"Les Pensières"*

Fondation Mérieux Conference Center  
Veyrier du Lac - France

*October 25 to 27, 2015*



des racines pour la vie • roots for life



## Steering Committee

Members	Institutions
Françoise Barré-Sinoussi	Institut Pasteur France
Jean-François Delfraissy	Agence Nationale de Recherche sur le Sida (ANRS) INSERM AVIESAN France
Marc P Girard	Académie Nationale de Médecine France
Roger Le-Grand	CEA/INSERM/Université Paris Sud France
Yves Levy	VRI / INSERM France
Benoît Miribel	Fondation Mérieux France

## Scientific Advisory Board

Members	Institutions
Galit Alter	Ragon Institute UK
Francis Barin	Université François-Rabelais & INSERM U966 France
Zhiwei Chen	AIDS Institute, The University of Hong Kong China
Marc P Girard	Académie Nationale de Médecine France
Roger Le-Grand	CEA/INSERM/Université Paris Sud France
Lynn Morris	National Institute for Communicable Diseases South Africa
Louis Picker	Oregon Health & Science University Vaccine and Gene Therapy Institute USA
Pascal Poignard	IAVI / TSRI USA
Sahra Rowland-Jones	Nuffield Department of Medicine, Oxford University UK
Gabriella Scarlatti	San Raffaele Scientific Institute Italia
Hanneke Schuitemaker	Janssen The Netherlands
Barbara Shacklett	University of California at Davis USA

## Organizing Committee

Members	Institutions
Marc P Girard	Académie Nationale de Médecine France
Cindy Grasso	Fondation Mérieux France
Christophe Longuet	Fondation Mérieux France
Valentina Picot	Fondation Mérieux France

# Scientific Programme

Sunday, October 25<sup>th</sup> 2015

## Introduction

Chairs: Jim Bradac and Jean François Delfraissy

12h30	Registration	
14h00-14h30	Welcome addresses	<ul style="list-style-type: none"><li>• Benoît Miribel</li><li>• Jean-François Delfraissy</li><li>• Marc Girard</li></ul>
14h30-15h15	The B Cell Pathway	Barton Haynes
15h15-16h00	The T cell pathway	Bruce Walker
16h00-16h45	<i>Coffee Break</i>	

## Session 1

### Blocking Virus Entry

Chairs: Lynn Morris and Robin Shattock

16h45-17h30	Impact of HIV phenotype on transmission and disease progression	Eric Hunter
17h30-17h50	Type I Interferons: Barriers or Pathways to Virus Entry?	Netanya Sandler-Utay
17h50-18h10	Induction of HIV-1 broadly neutralizing antibodies: The role of host and viral determinants	Alexandra Trkola
18h10-18h30	Untitled abstract	Michael Farzan
18h30-18h50	The role of immune activation and the microbiome in mucosal transmission of SIV	Jay A. Berzofsky
18h50-19h10	Inactivated AT-2 treated SIVmac239 and Lactobacillus plantarum (LP) as a candidate AIDS vaccine	Guido Silvestri
19h10-19h45	<i>General discussion</i>	
19h45	Welcome Reception and Diner	

Monday, October 26<sup>th</sup> 2015

## Session 2

### Broadly Neutralizing Antibodies

Chair: Hanneke Schuitemaker and Wayne Koff

8h00-8h45	Broadly neutralizing antibodies to HIV	Dennis Burton
8h45-9h05	Reproducible antibody lineages as templates for vaccine design	Peter Kwong
9h05-9h25	Broadly neutralizing antibody 8ANC195 recognizes closed and open conformational states of HIV-1 Env	Pamela Bjorkman
9h25-9h45	Antiviral Properties of Broadly Neutralizing HIV-1 Antibodies	Hugo Mouquet
9h45-10h00	General Discussion	
10h00-10h45	<i>Coffee Break</i>	

## Session 3

### Passive Immunization and VIP

Chair: Sarah Rowland-Jones and Pascal Poignard

10h45-11h30	Overview of HIV Antibodies for Prevention and Treatment	John Mascola
11h30-11h50	Passive Immunization for Prevention and Treatment of HIV	Barney Graham
11h50-12h10	Immunotherapy for HIV-1 in Humans	Michel Nussenzweig
12h10-12h30	Ability to Develop Broadly Neutralizing HIV-1 Antibodies is not Restricted by the Germline Immunoglobulin Gene Repertoire	Lynn Morris
12h30-12h40	Optimization of broadly neutralizing Abs for HIV prevention and treatment	Gary Nabel
12h40-13h00	General Discussion	
13h00	Lunch	

<b>Session 4</b>	<b>Antibody Effector Functions</b> Chair: Francis Barin and Christiane Moog	
------------------	--------------------------------------------------------------------------------	--

14h00-14h45	Introduction	Galit Alter
14h45-15h05	Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control	Margie Ackerman
15h05-15h25	ADCC antibodies and the prevention of HIV acquisition	Stephen Kent
15h25-15h45	Novel SHIV Design to Elicit Broadly Neutralizing Antibodies and Guide Iterative Vaccine Development	George Shaw
15h45-16h00	General Discussion	
16h00-16h45	<i>Coffee Break</i>	

<b>Session 5</b>	<b>Mucosal Immune Responses</b> Chair: Mario Clerici and Elizabeth Menu	
------------------	----------------------------------------------------------------------------	--

16h45-17h30	Prevention of HIV Infection at Mucosal Sites of HIV Exposure	Julie Mc Elrath
17h30-17h50	Characterizing antibodies from new populations	Julie Overbaugh
17h50-18h10	Mucosal IgA: Protection Against SHIV Infection by Passive and Active Immunization	Ruth Ruprecht
18h10-18h30	Natural control of HIV-1 infection in the uterine mucosa: a model for developing novel protective vaccine strategies?	Elizabeth Menu
18h30-18h50	The in vivo effects of anti- $\alpha 4\beta 7$ in rhesus macaques during acute and chronic infection	James Arthos
18h50-19h10	Mechanisms of HIV-1 restriction and dissemination mediated by intestinal mucosal myeloid cells	Gabriella Scarlatti
19h10-19h30	Abstract not provided	Jo-Ann Passmore
19h30-20h00	<i>General Discussion</i>	
20h00	Diner	

Tuesday, October 27<sup>th</sup> 2015

## Session 6

### Cellular Immune Responses

Chair: Barbara Shacklett and Louis Picker

8h00-8h45	Cytomegalovirus Vectors: Exceptional Efficacy from Unconventional Cellular Immune Responses	Louis Picker
8h45-9h05	T follicular helper cells are the major source of replication and infectious HIV in long-term ART treated subjects	Giuseppe Pantaleo
9h05-9h25	Peripheral T follicular helper cells responses in HIV vaccine trials	Hendrik Streeck
9h25-9h45	Relationship between CD4+ T cell subsets and the neutralisation breadth of the antibody response generated during HIV-1 infection	Persephone Borrow
9h45-10h05	From mechanism of action of MVA-HIV vaccine candidate to clinical trial	Olivier Schwartz
10h05-10h25	General Discussion	
10h25-11h00	<i>Coffee Break</i>	

## Session 7

### Update on Clinical trials

Chair: Galit Alter and Zhiwei Chen

11h00-11h45	HIV vaccines trials: Advancing into Efficacy	Glenda Gray
11h45-12h05	Update on clinical trials	Jerome Kim
12h05-12h25	Preclinical-to-Clinical HIV Vaccine Development	Dan Barouch
12h25-12h45	HIV-1 Vaccine Humoral Immunity, Immune Correlates and Mechanistic Insights	Georgia Tomaras
12h45-13h00	General Discussion	
13h00	Lunch	

<b>Session 8</b>	<b>Control of Virus reservoirs</b> Chair: Olivier Lambotte and Michaela Muller Trutwin
------------------	-------------------------------------------------------------------------------------------

14h15-15h00	Identifying The HIV Reservoir	Danny Douek
15h00-15h20	Persistent Inflammation during ART and its Potential Impact on Therapeutic Vaccines	Steven Deeks
15h20-15h40	Abstract not provided	Monsef Benkirane
15h40-16h00	Treatment with a TLR7 Agonist Induces Transient Viremia in SIV-Infected ART-Suppressed Monkeys	James Whitney
16h00-16h15	General Discussion	

<b>Session 9</b>	<b>Prospects and Conclusions</b> Chair: Patrice Debré and Gabriella Scarlatti
------------------	----------------------------------------------------------------------------------

16h15-16h35	Protection from heterologous SHIV infection by vaccination with a replication-competent VSV-HIV Env vaccine	Wayne Koff
16h35-17h00	Towards an HIV Cure: HIV remission as a first step	Asier Saez-Cirion
17h00-17h30	Conclusions	Françoise Barré-Sinoussi
17h30	End of Meeting	